Venus Remedies Ltd Hits Lower Circuit Amid Heavy Selling Pressure

Intraday Price Movement and Volatility

On 13 Mar 2026, Venus Remedies Ltd’s share price opened near its previous close but quickly succumbed to heavy selling, touching an intraday low of ₹881.15, marking a 5.0% decline from the prior day’s close. The stock’s high for the day was ₹944.75, which also represented a new 52-week and all-time high reached earlier in the session. This wide price range resulted in an intraday volatility of 5.36%, underscoring the heightened uncertainty and rapid shifts in investor sentiment.

The weighted average price for the day was closer to the low end of the band, indicating that the bulk of trading volume occurred near the lower price levels. Total traded volume stood at 34,587 shares (0.34587 lakh), with a turnover of ₹3.10 crore, reflecting moderate liquidity for a micro-cap stock. Despite this, the stock remains liquid enough to accommodate trade sizes of approximately ₹0.18 crore based on 2% of the five-day average traded value.

Heavy Selling Pressure and Circuit Breaker Trigger

The stock’s fall to the lower circuit limit was driven by unrelenting selling pressure, with many investors rushing to exit positions amid fears of a reversal after a prolonged seven-day rally. The day’s price band was set at 5%, and Venus Remedies Ltd hit the maximum permissible daily loss of ₹46.35 per share, triggering the lower circuit breaker and halting further declines for the day.

This sharp correction contrasts with the stock’s recent momentum, where it had been trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a strong uptrend. The sudden shift to panic selling suggests that profit-booking and cautious sentiment have temporarily overwhelmed buying interest.

Sector and Market Context

Venus Remedies Ltd underperformed its Pharmaceuticals & Biotechnology sector, which declined by 1.16% on the same day. The broader Sensex also fell by 1.31%, indicating a generally negative market environment. However, Venus Remedies’ 5.0% drop was significantly steeper than both benchmarks, highlighting the stock-specific pressures it faced.

Investor participation had surged recently, with delivery volume on 12 Mar rising by 167.42% to 87,960 shares compared to the five-day average, reflecting increased interest ahead of the correction. This heightened activity may have contributed to the volatility and the eventual circuit hit as traders scrambled to adjust positions.

Mojo Score Upgrade and Market Capitalisation

Venus Remedies Ltd’s Mojo Score currently stands at 74.0, reflecting a positive outlook based on a combination of fundamental and technical factors. The company was upgraded from a Hold to a Buy rating on 12 Mar 2026, signalling improved confidence from MarketsMOJO analysts. This upgrade was supported by the stock’s strong price momentum and favourable moving average trends.

Despite this, the company remains classified as a micro-cap with a market capitalisation of ₹1,179 crore. Micro-cap stocks are often subject to higher volatility and liquidity constraints, which can exacerbate price swings during periods of market stress or profit-taking.

Technical and Trading Insights

The stock’s recent performance had been characterised by a steady uptrend, with Venus Remedies trading comfortably above all major moving averages. However, the seven-day consecutive gains were abruptly halted as the stock reversed sharply on 13 Mar 2026. The lower circuit hit indicates that sellers dominated the session, with unfilled supply overwhelming demand.

Such a scenario often reflects panic selling, where investors rush to liquidate holdings to avoid further losses. The fact that the stock’s weighted average price was closer to the day’s low suggests that buyers were scarce, and sellers were willing to accept lower prices to exit positions.

Outlook and Investor Considerations

While the immediate price action appears negative, the underlying fundamentals and technical indicators remain supportive of a positive medium-term outlook. The Mojo Grade upgrade to Buy and the stock’s position above key moving averages suggest that this correction could be a temporary pullback rather than a sustained downtrend.

Investors should monitor trading volumes and price action in the coming sessions to gauge whether selling pressure abates or intensifies. Given the micro-cap status, volatility is expected to remain elevated, and careful risk management is advisable.

Summary

Venus Remedies Ltd’s sharp 5.0% decline to ₹881.15 on 13 Mar 2026, culminating in a lower circuit hit, highlights the risks inherent in micro-cap stocks despite positive technical signals and recent upgrades. Heavy selling pressure, panic-driven exits, and unfilled supply overwhelmed the stock, causing it to underperform both its sector and the broader market. Investors should weigh the recent correction against the company’s strong fundamentals and upgraded Mojo Grade, maintaining vigilance for further volatility in the near term.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →